Skip to main content
. Author manuscript; available in PMC: 2011 Aug 11.
Published in final edited form as: J Neurochem. 2007 May;101(3):749–756. doi: 10.1111/j.1471-4159.2006.04365.x

Fig. 3.

Fig. 3

Example of immunoreactivity of sera obtained from a PD patient and a control healthy individual with recombinant synuclein proteins. A membrane with full-length recombinant synucleins (Ponceau-S staining is shown in the top panel) was subsequently probed with PD serum GRSPD4 (middle panel) and control serum [c_3880] (bottom panel). α-S: α-synuclein, α-SA53T: α-synuclein with A53T mutation, β-S: β-synuclein, γ-S: γ-synuclein.

HHS Vulnerability Disclosure